MiMedx Group Inc. (MDXG)

5.98
NASDAQ : Health Technology
Prev Close 5.59
Day Low/High 5.62 / 5.99
52 Wk Low/High 4.95 / 18.25
Avg Volume 2.53M
Exchange NASDAQ
Shares Outstanding 111.03M
Market Cap 620.69M
EPS 0.10
P/E Ratio 18.03
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of MiMedx Group, Inc. (MDXG)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of MiMedx Group, Inc. (MDXG)

NEW YORK, June 8, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MiMedx Group, Inc.

NEW INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against MiMedx Group, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

NEW INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against MiMedx Group, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MiMedx Group, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Breaches Of Fiduciary Duties By Management Of MiMedx Group, Inc. - MDXG

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Breaches Of Fiduciary Duties By Management Of MiMedx Group, Inc. - MDXG

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by management of MiMedx Group, Inc.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Behalf Of MiMedx Group, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Behalf Of MiMedx Group, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces that it has commenced an investigation on behalf of MiMedx Group, Inc.

KASKELA LAW LLC: Investigation Of MiMedx Group, Inc. On Behalf Of Stockholders

KASKELA LAW LLC: Investigation Of MiMedx Group, Inc. On Behalf Of Stockholders

Kaskela Law LLC announces that it has commenced an investigation of MiMedx Group, Inc.

MiMedx Announces Executive To Lead Its International Operations And Provides Update On Company's International Progress

MiMedx Announces Executive To Lead Its International Operations And Provides Update On Company's International Progress

MARIETTA, Ga., June 7, 2018 /PRNewswire/ -- MiMedx Group, Inc.

MiMedx To Restate Certain Historical Financial Statements

MiMedx To Restate Certain Historical Financial Statements

Company to Restate Financial Statements for Fiscal Years 2012 through 2016, and Interim Periods of 2017 Related to Revenue Recognition

Noteworthy Tuesday Option Activity: MDXG, GERN, ZOES

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MiMedx Group Inc , where a total of 13,930 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 62.1% of MDXG's average daily trading volume over the past month of 2.2 million shares.

First Week Of July 20th Options Trading For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

First Week Of MDXG December 21st Options Trading

Investors in MiMedx Group Inc saw new options begin trading this week, for the December 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MiMedx Reports Unreviewed First Quarter Revenue Exceeded Upper End Of Its Guidance

COMPANY ANNOUNCES ITS REVENUE GUIDANCE FOR SECOND QUARTER AND INCREASES FULL YEAR REVENUE GUIDANCE

MIMEDX 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against MiMedx Group Inc. - MDXG

MIMEDX 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against MiMedx Group Inc. - MDXG

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc.

MiMedx To Highlight Efficacy Of Its Allografts In Presentations At SAWC Spring Conference

Breakfast Symposium to Underscore Statistically Significant Evidence of EpiFix® in Healing DFUs and VLUs

Washington Woes Slam Stocks: Cramer's 'Mad Money' Recap (Friday 4/13/18)

Washington Woes Slam Stocks: Cramer's 'Mad Money' Recap (Friday 4/13/18)

President Trump is creating a level of uncertainty that breeds selling. But Jim Cramer has your game plan for next week.

MIMEDX SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against MiMedx Group Inc. - MDXG

MIMEDX SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against MiMedx Group Inc. - MDXG

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc.

MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee

MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee

Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA